FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More
Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s Alzheimer’s drug Leqembi, which, according to Eisai, could “help reduce the burden on healthcare professionals and patients.”
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More Read More »
